spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Makena 

 HSMN NewsFeed - 2 Jan 2019
Slayback Pharma Announces FDA Approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml in a Multi-Dose Vial, the First Generic Equivalent of Makena(R) Injection 1,250 mg/ 5 ml Multi-Dose Vial
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 31 Aug 2018
Amneal Announces Partnership with American Regent on Generic Makena(R) and Progress on its Business Plan with Additional ANDA Approvals and Launches
Biopharmaceuticals Generics Distribution Product Launch
 HSMN NewsFeed - 17 Apr 2017
AMAG Submits Supplemental New Drug Application to FDA for Makena(R) (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 4 Apr 2017
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa(TM) (Prasterone)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2016
AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next Generation Development Programs for Makena(R) and Feraheme(R)
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2014
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2014
AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Dec 2012
K-V Pharmaceutical Receives Court Approval of Hologic Settlement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 17 Jun 2011
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Biopharmaceuticals Generics
 HSMN NewsFeed - 4 Feb 2011
FDA Approves Makena, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
Biopharmaceuticals FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.